Enhancing the Anti-Cancer Immune Response by Combining Radiotherapy and Immunotherapy

放射治疗与免疫治疗相结合增强抗癌免疫反应

• 批准号: nhmrc : 1122347
• 负责人: A/Pr Shankar Siva
• 金额: $ 18.02万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/enhancing-anti-cancer-radiotherapy-immunotherapy/946936
• 关键词: Enhancing; Anti; Cancer; Immune; Response

Lung cancer is the biggest cause of cancer related death in Australia. Recently, immune therapies have shown promise by unlocking the body’s own defenses to fight against lung cancer. I aim to maximise the effect of the anti-PD-1 immune therapy by ‘kick-starting’ the immune response with high-precision stereotactic ablative body radiotherapy (SABR). By completing clinical trials and biological research into the combination of therapies I hope to improve outcomes for patients with lung cancer.

肺癌是澳大利亚癌症相关死亡的最大原因。最近，免疫疗法通过释放人体自身的防御来对抗肺癌，显示出了希望。我的目标是通过高精度立体定向消融体放疗（SABR）“启动”免疫反应，最大限度地提高抗pd -1免疫治疗的效果。通过完成临床试验和生物学研究，我希望能改善肺癌患者的治疗效果。